News from hoffmann-la roche limited (roche canada) A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

May 20, 2020, 10:49 ET Health Canada grants market authorization to ROZLYTREK® (entrectinib) for ROS1-positive, locally advanced or metastatic non-small cell lung cancer patients, not previously treated with crizotinib(1)

Data show responses in 73% of patients who were treated with Rozlytrek1 MISSISSAUGA, ON, May 20, 2020 /CNW/ - Hoffmann-La Roche Limited (Roche Canada) is pleased to announce that Health Canada has...


Nov 28, 2019, 08:00 ET Health Canada approves Kadcyla® (trastuzumab emtansine) for the treatment of HER2-positive early breast cancer after surgery(1)

Data show patients had a 50% reduction in risk of recurrence compared to treatment with Herceptin® (trastuzumab) after surgery2 MISSISSAUGA, ON, Nov. 28, 2019 /CNW/ - Hoffmann-La Roche Limited (Roche ...


Sep 27, 2019, 13:19 ET Health Canada approves Tecentriq® in combination with chemotherapy (nab-paclitaxel) as first immunotherapy treatment for aggressive form of breast cancer(1)

New approval provides patients with PD-L1 positive, metastatic triple-negative breast cancer with an additional treatment option that significantly reduced the risk of disease progression by 38%...


May 29, 2019, 08:00 ET Health Canada approves TECENTRIQ® (atezolizumab) combination therapy for first-line treatment of metastatic non-squamous non-small cell lung cancer

Data show this new option can help some metastatic NSCLC patients live significantly longer1 MISSISSAUGA, ON, May 29, 2019 /CNW/ - Hoffmann-La Roche Limited (Roche Canada) announced today that Health ...


Sep 04, 2018, 08:00 ET Health Canada approves PERJETA® (pertuzumab) for the treatment of HER2-positive early breast cancer after surgery

New treatment option can significantly reduce risk of disease recurrence or death, preventing breast cancer from returning and progressing to an incurable stage1,2 MISSISSAUGA, ON, Sept. 4, 2018...


Jun 13, 2018, 08:00 ET ALECENSARO® (alectinib) approved by Health Canada for first-line treatment of ALK-positive lung cancer

Targeted oral treatment shown to reduce risk of death or disease progression by more than half compared to standard of care, while also reducing the risk of tumours spreading to and growing in the...


Apr 09, 2018, 08:00 ET Health Canada approves TECENTRIQ® (atezolizumab) for the treatment of patients with metastatic non-small cell lung cancer

TECENTRIQ provides a new cancer immunotherapy option for Canadians living with the difficult disease MISSISSAUGA, ON, Apr. 9, 2018 /CNW/ - Hoffmann-La Roche Limited (Roche Canada) announced today...


Nov 14, 2017, 07:30 ET Rewrite Cancer Innovation Challenge To Create Change for a Better Future for Cancer Care

Roche Canada is calling on great Canadian minds to come together and rewrite the story of cancer for tomorrow's patients MISSISSAUGA, ON, Nov. 14, 2017 /CNW/ - Hoffmann-La Roche Limited (Roche...


Apr 18, 2017, 08:00 ET Health Canada Approves TECENTRIQ™ (atezolizumab) for Patients with Locally Advanced and Metastatic Bladder Cancer

Early data suggests TECENTRIQ shows strong efficacy for metastatic bladder cancer patients, offering the first new treatment option in more than 30 years1 MISSISSAUGA, ON, April 18, 2017 /CNW/ -...


Oct 02, 2013, 13:00 ET A New Home for Roche Canada

Grand Opening Celebration to officially open the doors of 7070 Mississauga Road MISSISSAUGA, ON, Oct. 2, 2013 /CNW/ - Hoffmann-La Roche Limited (Roche Canada) celebrated today the Grand Opening of...